Lixisenatide, a drug developed to treat type 2 diabetes, shows neuroprotective effects in a mouse model of Alzheimer's disease

  title={Lixisenatide, a drug developed to treat type 2 diabetes, shows neuroprotective effects in a mouse model of Alzheimer's disease},
  author={Paula L. McClean and Christian H{\"o}lscher},

Neuroprotective effects of lixisenatide and liraglutide in the MPTP mouse model of Parkinson's disease.

Both liraglutide and lixisenatide are superior to exendin-4, and both drugs show promise as a novel treatment of PD.

Long-Term Treatment with Liraglutide, a Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist, Has No Effect on β-Amyloid Plaque Load in Two Transgenic APP/PS1 Mouse Models of Alzheimer’s Disease

In conclusion, long-term liraglutide treatment exhibited no effect on cerebral plaque load in two transgenic mouse models of low- and high-grade amyloidosis, which suggests differential sensitivity to long- term lirAGlutid treatment in various transgenic mice models mimicking distinct pathological hallmarks of AD.

Glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide analogues as novel treatments for Alzheimer’s and Parkinson’s disease

In a pilot study on patients with AD, the GLP-1 analogue liraglutide showed good protective effects in 18F-fluorodeoxyglucose (18F-FDG)-PET brain imaging and the disease-related decay of brain activity had been completely stopped by the drug.

The neuroprotective effects of glucagon-like peptide 1 in Alzheimer’s and Parkinson’s disease: An in-depth review

The neuroprotective pathways that are induced following GLP-1R activation in neurons, microglia and astrocytes include synaptic protection, improvements in cognition, learning and motor function, amyloid pathology-ameliorating properties and the suppression of Ca2+ deregulation and ER stress.

Role of liraglutide in Alzheimer’s disease pathology

The effects of LRGT on animal models show significant benefits in AD pathology and cognitive impairment, while studies in patients are limited and ongoing clinical trials will probably provide more definitive conclusions on the role ofLRGT in AD patients.

Neuroprotective Actions of Glucagon-Like Peptide-1 (GLP-1) Analogues in Alzheimer’s and Parkinson’s Diseases

Long-acting glucagon-like peptide-1 analogues marketed for treatment of type 2 diabetes mellitus have been tested and have shown encouraging protective actions in experimental models of AD and PD as well as in initial clinical trials.



The Diabetes Drug Liraglutide Prevents Degenerative Processes in a Mouse Model of Alzheimer's Disease

In APP/PS1 mice, liraglutide prevented memory impairments in object recognition and water maze tasks, and prevented synapse loss and deterioration of synaptic plasticity in the hippocampus, commonly observed in this model, suggesting that GLP-1 analogs represent a novel treatment strategy for Alzheimer's disease.

Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis

The results suggest that these novel incretin analogues cross the blood brain barrier and show physiological activity and neurogenesis in the brain, which may be of use as a treatment of neurodegenerative diseases.

Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases.

GLP-1 mimetics show great promise as a novel treatment for neurodegenerative conditions because of the substantial body of evidence that these mimetics have neuroprotective and anti-inflammatory effects.

Insulin, incretins and other growth factors as potential novel treatments for Alzheimer's and Parkinson's diseases.

The present review summarizes the range of neuroprotective effects that these drugs have demonstrated and emphasizes the great promise that this approach has in providing novel treatments that have protective and even restorative properties that no current drug treatment can offer.

Lixisenatide, a novel GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus.

The results of phase III trials are awaited for confirmation of the anticipated effects of lix Eisenatide on glycemic measures and weight; favorable results would place lixisenatide for consideration among other GLP-1R agonists in the treatment armamentarium for T2DM.